Skip to main content

Nephrology Specialty Report 2022


Message From the Chief

Introducing the Barbara T. Murphy Division of Nephrology

The newly renamed Barbara T. Murphy Division of Nephrology moved forward on a broad variety of fronts in 2021.

Mount Sinai Health System and the Icahn School of Medicine at Mount Sinai, including our Division of Nephrology, have long placed a special emphasis on translational research—moving discoveries from bench to bedside to make a real difference in our patients’ lives.

In 2021, as described in this report, we marked a major milestone in this area when Renalytix, a company co-founded by several Icahn Mount Sinai faculty members, brought its first product into clinical use: KidneyIntelX, which uses a proprietary algorithm and a variety of data inputs to assess disease progression risk among early-stage CKD patients with type 2 diabetes. The inputs include clinical data from patients’ electronic health records and three blood-based biomarkers.

Learn More